table_specific

What was the average sales for the top 25% of Learningrx centers in the sample?

Learningrx Franchise · 2025 FDD

Answer from 2025 FDD Document

Sample: Top 25% Mid-Top Mid-Lower Bottom
25% 25% 25%
# of Centers: 11 10 10 10 4
Top Sales $893,375 $486,808 $287,188 $167,835 $376,730
Low Sales $507,737 $300,712 $172,105 $35,673 $133,094
Median Sales $601,971 $391,046 $229,711 $75,215 $195,526
Average Sales $631,577 $402,343 $229,935 $85,218 $225,219
Centers meeting or 2 / 18% 5 / 50% 5 / 50% 3 / 30% 1 / 25%
exceeding average:

Source: Item 19 — FINANCIAL PERFORMANCE REPRESENTATIONS (FDD pages 46–48)

What This Means (2025 FDD)

According to Learningrx's 2025 Franchise Disclosure Document, the average sales for the top 25% of Learningrx centers in the sample was $631,577. This data is based on the gross revenue records from franchisees for the fiscal year ending September 30, 2024. The top 25% represents 11 centers with the highest total revenue. The top sales for this group reached $893,375, while the low sales were $507,737, and the median sales were $601,971.

For a prospective Learningrx franchisee, this financial performance representation offers insight into the potential revenue that can be generated. It is important to note that the financial performance can vary significantly between locations. The document also shows that 2 out of the 11 centers, or 18%, in the top 25% met or exceeded the average sales of $631,577.

It is important for potential franchisees to understand that these figures are based on historical data and that individual results may differ. Learningrx states explicitly that there is no assurance that a franchisee will earn as much. The FDD also mentions that written substantiation for the financial performance representation will be made available to the prospective franchisee upon reasonable request, which is a common practice in franchising to ensure transparency and provide further details.

Disclaimer: This information is extracted from the 2025 Franchise Disclosure Document and is provided for research purposes only. It does not constitute legal or financial advice. Consult with a franchise attorney before making any investment decisions.